Vitamin C has antitumour effects of PLX4032 in BRAF(MT) thyroid cancer cells by relieving the feedback activation of MAPK/ERK and PI3K/AKT pathway. A combination of PLX4032 and vitamin C can be a potential therapeutic approach to treat BRAF(MT) thyroid cancer. The gene discussed is AKT1; the disease is thyroid cancer.